KEGG   DRUG: Cabotegravir and rilpivirine
Entry
D11966            Mixture   Drug                                   
Name
Cabotegravir and rilpivirine;
Cabenuva (TN)
Product
CABENUVA (ViiV Healthcare Company)
Component
(Cabotegravir [DR:D10548] | Cabotegravir sodium [DR:D10549]), (Rilpivirine [DR:D09720] | Rilpivirine hydrochloride [DR:D09958])
Class
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
 DG02924  UGT substrate
  DG03183  UGT1A1 substrate
  DG03188  UGT1A9 substrate
Remark
Product: D11966<US>
Efficacy
Antiviral
  Disease
HIV-1 infection [DS:H01563]
Comment
Cabotegravir is primarily metabolized by UGT1A1 with some contribution from UGT1A9.
Rilpivirine is primarily metabolized by CYP3A.
Target
HIV-1 reverse transcriptase [KO:K24802]
HIV-1 integrase [KO:K24803]
  Pathway
ko03230  Viral genome structure
ko03240  Viral replication
ko03250  Viral life cycle - HIV-1
Metabolism
Enzyme: UGT1A1 [HSA:54658], CYP3A [HSA:1576 1577 1551]; UGT1A9 [HSA:54600]
Interaction
Brite
USP drug classification [BR:br08302]
 Antivirals
  Anti-HIV Combinations
   Cabotegravir/ Rilpivirine
    D11966  Cabotegravir and rilpivirine
Drug groups [BR:br08330]
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   D11966  Cabotegravir and rilpivirine
  DG02924  UGT substrate
   DG03183  UGT1A1 substrate
    D11966  Cabotegravir and rilpivirine
   DG03188  UGT1A9 substrate
    D11966  Cabotegravir and rilpivirine
Antimicrobials [BR:br08307]
 Antivirals
  Genome replication inhibitor
   HIV integrase inhibitor
    D11966  Cabotegravir and rilpivirine <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11966
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D11966
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system